Special Issue

Pulmonary Arterial Hypertension (PAH)

Message from the Guest Editor

Pulmonary arterial hypertension (PAH) is a rare but devastating disease that carries a terrible prognosis. Pathologically PAH is characterized by sustained vasoconstriction and progressive obliteration of small resistance pulmonary arteries. Current treatments target the sustained vasoconstriction but the prognosis remains poor. There is currently limited information on biomarkers that indicate a patient response to these therapies. There is also an unmet need to develop new treatments that specifically target the progressive vasculopathy in these patients. This Special Issue will provide an Open Access opportunity to publish research work and review articles related to the novel biomarkers, new molecular insights and potential therapeutic targets.

Guest Editor

Dr. Allan Lawrie
Department of Cardiovascular Science, University of Sheffield, Sheffield, UK

Deadline for manuscript submissions

closed (15 February 2014)

Diseases

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/si/2847

Diseases
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diseases@mdpi.com

mdpi.com/journal/diseases

Diseases

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/journal/diseases

About the Journal

Message from the Editorial Board

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets. *Diseases* is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Maurizio Battino
Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

Prof. Dr. Omar Cauli
Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

MDPI